—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Sarepta Therapeutics Inc (SRPT) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for SRPT, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 1.55 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How SRPT has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 1.55 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Sarepta Therapeutics Inc moved 1.55% on average · correlation 0.18 · higher than 97% of US names
  • Beta, last 3 months 1.87 more rate-sensitive lately than over the year
  • On the 10 worst bond days −2.67% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −2.96% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · United States · 8 names with week and year-to-date

Peer group

Biotechnology · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against SRPT on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Sarepta Therapeutics Inc

SRPT in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Sarepta develops RNA-targeted and gene therapies for rare diseases, focused mainly on Duchenne muscular dystrophy and related muscle disorders. Its approved drugs, including Exondys 51, Vyondys 53 and Amondys 45, use exon-skipping to address specific dystrophin gene mutations, and Elevidys is an AAV gene therapy for the same condition. Earlier-stage programmes target other genetic muscle diseases through partnerships with Roche, Arrowhead and academic centres. It is headquartered in Cambridge, Massachusetts.
Where it sits in the stack
Sarepta carries no seat in Rubin or Halo, the diary's AI-linked indices, since its business sits outside the build-out chain entirely. Within our universe it belongs to the Healthcare sector, Biotechnology industry, tracked for its own therapeutic pipeline rather than any AI exposure.
Who it is priced against
Closelooknet has not assigned it a peer group in our data; the market often compares it with Alnylam Pharmaceuticals, another company built around RNA-based rare-disease treatments.
Why Closelooknet tracks it
It is a Russell 1000 constituent; it carries no Closelooknet score yet, as no module has been recorded, and the diary has not quoted it in any edition.
What the diary watches
The diary watches how Elevidys safety data and uptake evolve, since gene-therapy setbacks or approvals could reshape how the rest of the pipeline is read.

Sarepta Therapeutics Inc (SRPT) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Sarepta Therapeutics Inc (SRPT)?

Sarepta Therapeutics Inc trades as SRPT on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is SRPT in a Closelooknet index?

Not currently — Sarepta Therapeutics Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does SRPT trade against its moving averages?

Mixed moving-average stack: Trades -0.1% vs the 50-day and -2.8% vs the 200-day average, 26.3% below the 52-week high and +27.2% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Sarepta Therapeutics Inc trade when bond yields rise?

Over the past year Sarepta Therapeutics Inc had a beta of 1.55 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 97% of US names. On the 10 sessions in which long bonds fell most it moved −2.67% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Sarepta Therapeutics Inc do?

Sarepta develops RNA-targeted and gene therapies for rare diseases, focused mainly on Duchenne muscular dystrophy and related muscle disorders. Its approved drugs, including Exondys 51, Vyondys 53 and Amondys 45, use exon-skipping to address specific dystrophin gene mutations, and Elevidys is an AAV gene therapy for the same condition. Earlier-stage programmes target other genetic muscle diseases through partnerships with Roche, Arrowhead and academic centres. Closelooknet has not assigned it a peer group in our data; the market often compares it with Alnylam Pharmaceuticals, another company built around RNA-based rare-disease treatments.

Where does Sarepta Therapeutics Inc sit in the AI build-out?

Sarepta carries no seat in Rubin or Halo, the diary's AI-linked indices, since its business sits outside the build-out chain entirely. Within our universe it belongs to the Healthcare sector, Biotechnology industry, tracked for its own therapeutic pipeline rather than any AI exposure. It is a Russell 1000 constituent; it carries no Closelooknet score yet, as no module has been recorded, and the diary has not quoted it in any edition.

What does this page show?

A live price chart with SMA overlays and drawing tools for SRPT, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.